A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer

About this Study

To assess the safety of ASG-22CE for the treatment of urothelial cancer

Sponsor Protocol ID:SGN22E-002
IRB Number:2020-0197
Actively Enrolling
Phase 1
December 21, 2020
Eligibility Criteria
18 years old
Both Male and Female

Inclusion Criteria1.  Minimum age of 18 years with locally advanced or metastatic cancer of the bladder, renal pelvis, ureter, or urethra.

2. Have adequate organ function.

Exclusion Criteria1.   Conditions requiring high doses of steroids or other immunosuppressive medications.

2.  History of another malignancy within 3 years.

3.  Receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal).

4.  Hepatitis B, C, or HIV infection. 

5.  History of stroke.

7.  Active tuberculosis.

Categories Click category to view its trials.
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:Henegan, John C, M.D.
How to participate in our Clinical Trials